cMet emerges as the latest genetic mutation that could soon see targeted treatments become available.
Approvals for new uses of old drugs should far outweigh nods for novel projects in June.
Peloton Therapeutics’ approach to fighting kidney tumours has apparently convinced Merck & Co, which is to pay $1.05bn for the company on the back of relatively…
The group follows licensing deals with Dainippon and Roivant with a pivotal study win.
As the plot thickens around the trigger for Aveo’s equity raise, the EU regulator considers pulling the group's renal cancer drug from the market.
After two checkpoint combo trials flopped last month Syndax celebrates an unexpected win in a third.
A patient death notwithstanding, Chi-Med reckons results from the Tatton study justify its US registration strategy.
Pfizer/Merck KGaA scrap a pivotal trial, partly because it tested Bavencio against what is no longer the relevant standard of care.
Targeting a mechanism of resistance to first-generation BTK inhibitors has caught the attention of biotechs like Arqule, which claimed a major success last week.